Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.
Alteri C, Surdo M, Bellocchi MC, Saccomandi P, Continenza F, Armenia D, Parrotta L, Carioti L, Costa G, Fourati S, Di Santo F, Scutari R, Barbaliscia S, Fedele V, Carta S, Balestra E, Alcaro S, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V. Alteri C, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2015 Aug;59(8):4870-81. doi: 10.1128/AAC.00137-15. Epub 2015 Jun 8. Antimicrob Agents Chemother. 2015. PMID: 26055363 Free PMC article.
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, Katlama C, Benhamou Y, Calvez V. Delaugerre C, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2002 May;46(5):1586-8. doi: 10.1128/AAC.46.5.1586-1588.2002. Antimicrob Agents Chemother. 2002. PMID: 11959607 Free PMC article.
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.
Rituximab therapy for HIV-associated Castleman disease.
Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N. Marcelin AG, et al. Blood. 2003 Oct 15;102(8):2786-8. doi: 10.1182/blood-2003-03-0951. Epub 2003 Jul 3. Blood. 2003. PMID: 12842986 Free article.
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C, Gourlain K, Tubiana R, Carcelain G, Marcelin AG, Chouquet C, Mouroux M, Duvivier C, Autran B, Costagliola D, Katlama C, Calvez V. Delaugerre C, et al. Among authors: marcelin ag. Antivir Ther. 2003 Jun;8(3):233-7. Antivir Ther. 2003. PMID: 12924540 Clinical Trial.
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Wirden M, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004. Antimicrob Agents Chemother. 2004. PMID: 14742228 Free PMC article. Clinical Trial.
486 results